Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Veracyte, Inc. (VCYT) is a molecular diagnostics company operating in the precision medicine and clinical genomics industries. The company develops and commercializes genomic tests that help clinicians make more informed diagnostic and treatment decisions, particularly in oncology and pulmonary disease. Veracyte’s products are primarily used to improve diagnostic accuracy, reduce unnecessary invasive procedures, and guide personalized patient care.
The company’s core revenue is driven by its genomic diagnostic tests, most notably Afirma, Decipher, Percepta, and Envisia, which are ordered by physicians and reimbursed by commercial and government payers. Veracyte serves hospitals, academic medical centers, and community-based healthcare providers, with a strategic focus on high-impact diagnostic categories where traditional pathology has limitations. Founded in 2008, Veracyte evolved from a single-test diagnostics company into a multi-platform genomic diagnostics provider through internal development and acquisitions, expanding both its clinical focus and geographic reach.
Business Operations
Veracyte operates primarily through its integrated diagnostics model, combining proprietary genomic classifiers, bioinformatics, and centralized laboratory services. Its main business segments include Endocrine Diagnostics, Urologic Oncology, and Pulmonary and Thoracic Diagnostics, with each segment centered on a specific group of genomic tests that generate revenue on a per-test basis. The company performs testing in its own CLIA-certified laboratories, allowing it to control quality, data analytics, and test innovation.
The company conducts operations in both the United States and Europe, supported by laboratory and commercial infrastructure. A key subsidiary is HalioDx, which Veracyte acquired to expand its presence in spatial biology and immuno-oncology diagnostics. Veracyte also collaborates with pharmaceutical companies and research institutions to support biomarker development and companion diagnostic opportunities, though its primary revenue remains clinical testing services.
Strategic Position & Investments
Veracyte’s strategy focuses on expanding its diagnostic menu, increasing physician adoption, and strengthening payer reimbursement coverage. Growth initiatives include extending existing tests into new clinical indications, launching next-generation genomic and spatial biology platforms, and increasing utilization in international markets. The company has emphasized operational leverage by integrating acquired technologies into its centralized laboratory and commercial infrastructure.
A major strategic investment was the acquisition of HalioDx, which added the Immunoscore and spatial biology capabilities to Veracyte’s portfolio, positioning the company in emerging oncology diagnostics markets. Veracyte is also investing in artificial intelligence–driven analytics and RNA sequencing technologies to enhance diagnostic accuracy and scalability. These initiatives align with its long-term goal of becoming a leading provider of clinically actionable genomic diagnostics across multiple disease areas.
Geographic Footprint
Veracyte is headquartered in South San Francisco, California, and maintains a strong operational presence in the United States, which represents the majority of its revenue. The company also has significant operations in Europe, particularly through laboratory and commercial activities in France, supporting both clinical testing and research initiatives.
Beyond its core markets, Veracyte distributes its tests and technologies across multiple international regions through direct sales and partnerships, including parts of Western Europe and other select global healthcare markets. Its international footprint supports clinical adoption, pharmaceutical collaborations, and long-term expansion opportunities in precision diagnostics worldwide.
Leadership & Governance
Veracyte is led by an executive team with experience in molecular diagnostics, life sciences, and healthcare commercialization. The company emphasizes a strategy centered on scientific rigor, clinical utility, and disciplined growth, with leadership focused on expanding test adoption while maintaining regulatory and reimbursement compliance.
Key executives include:
- Marc Stapley – President and Chief Executive Officer
- Craig Hallum – Chief Financial Officer
- John Hanna – Chief Commercial Officer
- Richard H. Bell – Chief Medical Officer
- Rebecca Chambers – Chief Legal Officer and Corporate Secretary
The company was previously led by Bonnie Anderson, who played a central role in founding and scaling Veracyte’s early diagnostic platforms, helping establish its position in genomic testing prior to the current leadership team.